Market: NMS |
Currency: USD
Address: 101 Glen Lennox Drive
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
Show more
📈 Tenax Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$28.67
-
Upside/Downside from Analyst Target:
95.01%
-
Broker Call:
14
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Tenax Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2026-03-10 | -0.38 |
| 2025-11-12 | -0.4 |
| 2025-08-13 | -0.27 |
| 2025-05-14 | -0.28 |
| 2025-03-25 | -0.18 |
| 2024-11-13 | -0.19 |
| 2024-08-13 | -1.83 |
| 2024-05-14 | -3.12 |
| 2024-03-28 | -8.64 |
| 2023-11-13 | -6.4 |
| 2023-08-14 | -4 |
| 2023-05-15 | -12 |
| 2023-03-31 | -72.8 |
| 2022-11-10 | -176 |
| 2022-08-11 | -176 |
| 2022-05-16 | -176 |
| 2022-03-29 | -64 |
| 2021-11-15 | -240 |
| 2021-08-17 | -160 |
| 2021-05-17 | -214.74 |
| 2021-03-31 | -960 |
| 2020-11-16 | -288 |
| 2020-08-14 | -368 |
| 2020-05-15 | -608 |
| 2020-03-30 | -672 |
📰 Related News & Research
🔍 View more Reports
